The Human Phenotype Ontology in 2017 by Kohler, S. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/169849
 
 
 
Please be advised that this information was generated on 2017-12-07 and may be subject to
change.
Published online 24 November 2016 Nucleic Acids Research, 2017, Vol. 45, Database issue D865–D876
doi: 10.1093/nar/gkw1039
The Human Phenotype Ontology in 2017
Sebastian Ko¨hler1,*, Nicole A. Vasilevsky2, Mark Engelstad2, Erin Foster2, Julie McMurry2,
Se´gole`ne Ayme´3, Gareth Baynam4,5, Susan M. Bello6, Cornelius F. Boerkoel7, Kym
M. Boycott8, Michael Brudno9, Orion J. Buske9, Patrick F. Chinnery10,11,
Valentina Cipriani12,13, Laureen E. Connell14, Hugh J.S. Dawkins15, Laura E. DeMare14,
Andrew D. Devereau16, Bert B.A. de Vries17, Helen V. Firth18, Kathleen Freson19,
Daniel Greene20,21, Ada Hamosh22, Ingo Helbig23,24, Courtney Hum25, Johanna A. Ja¨hn24,
Roger James11,21, Roland Krause26, Stanley J. F. Laulederkind27, Hanns Lochmu¨ller28,
Gholson J. Lyon29, Soichi Ogishima30, Annie Olry31, Willem H. Ouwehand20,
Nikolas Pontikos12,13, Ana Rath31, Franz Schaefer32, Richard H. Scott16, Michael Segal33,
Panagiotis I. Sergouniotis34, Richard Sever14, Cynthia L. Smith6, Volker Straub28,
Rachel Thompson28, Catherine Turner28, Ernest Turro20,21, Marijcke W.M. Veltman11,
Tom Vulliamy35, Jing Yu36, Julie von Ziegenweidt20, Andreas Zankl37,38, Stephan Zu¨chner39,
Tomasz Zemojtel1, Julius O.B. Jacobsen16, Tudor Groza40,41, Damian Smedley16,
Christopher J. Mungall42, Melissa Haendel2 and Peter N. Robinson43,44,*
1Institute for Medical Genetics and Human Genetics, Charite´-Universita¨tsmedizin Berlin, Augustenburger Platz 1,
13353 Berlin, Germany, 2Library and Department of Medical Informatics and Clinical Epidemiology, Oregon Health &
Science University, Portland, OR 97239, USA, 3Institut du Cerveau et de la Moelle e´pinie`re––ICM, CNRS UMR
7225––Inserm U 1127––UPMC-P6 UMR S 1127, Hoˆpital Pitie´-Salpeˆtrie`re, 47, bd de l’Hoˆpital, 75013 Paris, France,
4Western Australian Register of Developmental Anomalies and Genetic Services of Western Australia, King Edward
Memorial Hospital Department of Health, Government of Western Australia, Perth, WA 6008, Australia, 5School of
Paediatrics and Child Health, University of Western Australia, Perth, WA 6008, Australia, 6The Jackson Laboratory,
600 Main St, Bar Harbor, ME 04609, USA, 7Imagenetics Research, Sanford Health, PO Box 5039, Route 5001, Sioux
Falls, SD 57117-5039, USA, 8Children’s Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa,
Ontario, Canada, 9Department of Computer Science, University of Toronto, Toronto, ON M5S 2E4, Canada Centre for
Computational Medicine, Hospital for Sick Children, Toronto, ON M5G 1L7, Canada, 10Department of Clinical
Neurosciences, School of Clinical Medicine, University of Cambridge, Cambridge CB2 0QQ, UK, 11NIHR Rare
Diseases Translational Research Collaboration, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK, 12UCL
Institute of Ophthalmology, Department of Ocular Biology and Therapeutics, 11–43 Bath Street, London EC1V 9EL,
UK, 13UCL Genetics Institute, University College London, London WC1E 6BT, UK, 14Cold Spring Harbor Laboratory
Press, Cold Spring Harbor, NY, USA, 15Office of Population Health Genomics, Public Health Division, Health
Department of Western Australia, 189 Royal Street, Perth, WA, 6004 Australia, 16Genomics England, Queen Mary
University of London, Dawson Hall, Charterhouse Square, London EC1M 6BQ, UK, 17Department of Human
Genetics, Radboud University, University Medical Centre, Nijmegen, The Netherlands, 18Wellcome Trust Sanger
Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK, 19Department of Cardiovascular
Sciences, Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium, 20Department of
Haematology, University of Cambridge, NHS Blood and Transplant Centre, Long Road, Cambridge CB2 0PT, UK,
21Medical Research Council Biostatistics Unit, Cambridge Institute of Public Health, Cambridge Biomedical Campus,
Cambridge, UK, 22McKusick-Nathans Institute of Genetic Medicine, Department of Pediatrics, Johns Hopkins
University School of Medicine, Baltimore, MD, USA, 23Division of Neurology, The Children’s Hospital of Philadelphia,
3501 Civic Center Blvd, Philadelphia, PA 19104, USA, 24Department of Neuropediatrics, University Medical Center
*To whom correspondence should be addressed. Tel: +1 860 837 2095; Email: peter.robinson@jax.org
Correspondence may also be addressed to Sebastian Ko¨hler. Email: dr.sebastian.koehler@gmail.com
C© The Author(s) 2016. Published by Oxford University Press on behalf of Nucleic Acids Research.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/), which
permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com
D866 Nucleic Acids Research, 2017, Vol. 45, Database issue
Schleswig-Holstein (UKSH), Kiel, Germany, 25Centre for Computational Medicine, The Hospital for Sick Children,
Toronto, ON M5G 1H3, Canada, 26LuxembourgCentre for Systems Biomedicine, University of Luxembourg, 7,
avenue des Hauts-Fourneaux, L-4362 Esch-sur-Alzette, Luxembourg, 27Human and Molecular Genetics Center,
Medical College of Wisconsin, USA, 28John Walton Muscular Dystrophy Research Centre, MRC Centre for
Neuromuscular Diseases, Institute of Genetic Medicine, University of Newcastle, Newcastle upon Tyne, UK,
29Stanley Institute for Cognitive Genomics, Cold Spring Harbor Laboratory, New York, NY 11797, USA, 30Dept of
Bioclinical Informatics, Tohoku Medical Megabank Organization, Tohoku University, Tohoku Medical Megabank
Organization Bldg 7F room #741,736, Seiryo 2-1, Aoba-ku, Sendai Miyagi 980-8573 Japan, 31Orphanet––INSERM,
US14, Plateforme Maladies Rares, 96 rue Didot, 75014 Paris, France, 32Division of Pediatric Nephrology and KFH
Children’s Kidney Center, Center for Pediatrics and Adolescent Medicine, 69120 Heidelberg, Germany,
33SimulConsult Inc., 27 Crafts Road, Chestnut Hill, MA 02467, USA, 34Manchester Royal Eye Hospital & University of
Manchester, Manchester M13 9WL, UK, 35Blizard Institute, Barts and The London School of Medicine and Dentistry,
Queen Mary University of London, London E1 2AT, UK, 36Nuffield Department of Clinical Neurosciences, University
of Oxford, Level 6, West Wing, John Radcliffe Hospital, Oxford OX3 9DU, UK, 37Discipline of Genetic Medicine,
Sydney Medical School, The University of Sydney, Australia, 38Academic Department of Medical Genetics, Sydney
Childrens Hospitals Network (Westmead), Australia, 39JD McDonald Department of Human Genetics and Hussman
Institute for Human Genomics, University of Miami, Miami, FL, USA, 40Garvan Institute of Medical Research,
Darlinghurst, Sydney, NSW 2010, Australia, 41St Vincent’s Clinical School, Faculty of Medicine, UNSW Australia,
42Environmental Genomics and Systems Biology Division, Lawrence Berkeley National Laboratory, 1 Cyclotron
Road, Berkeley, CA 94720, USA, 43The Jackson Laboratory for Genomic Medicine, 10 Discovery Drive, Farmington,
CT 06032, USA and 44Institute for Systems Genomics, University of Connecticut, Farmington, CT 06032, USA
Received September 20, 2016; Editorial Decision October 18, 2016; Accepted October 28, 2016
ABSTRACT
Deep phenotyping has been defined as the pre-
cise and comprehensive analysis of phenotypic ab-
normalities in which the individual components of
the phenotype are observed and described. The
three components of the Human Phenotype Ontology
(HPO; www.human-phenotype-ontology.org) project
are the phenotype vocabulary, disease-phenotype
annotations and the algorithms that operate on
these. These components are being used for compu-
tational deep phenotyping and precision medicine as
well as integration of clinical data into translational
research. The HPO is being increasingly adopted
as a standard for phenotypic abnormalities by di-
verse groups such as international rare disease or-
ganizations, registries, clinical labs, biomedical re-
sources, and clinical software tools and will thereby
contribute toward nascent efforts at global data ex-
change for identifying disease etiologies. This up-
date article reviews the progress of the HPO project
since the debut Nucleic Acids Research database
article in 2014, including specific areas of expan-
sion such as common (complex) disease, new al-
gorithms for phenotype driven genomic discovery
and diagnostics, integration of cross-species map-
ping efforts with the Mammalian Phenotype Ontol-
ogy, an improved quality control pipeline, and the
addition of patient-friendly terminology.
INTRODUCTION
The Human Phenotype Ontology (HPO) provides compre-
hensive bioinformatic resources for the analysis of human
diseases and phenotypes, offering a computational bridge
between genome biology and clinical medicine. The HPO
was initially published in 2008 (1) with the goal of enabling
the integration of phenotype information across scientific
fields and databases. Since then, the project has grown in
terms of coverage, scope and sophistication, and has be-
come a core component of theMonarch Initiative, allowing
computational cross-species analysis (2).
HPO has also become part of the core Orphanet (3)
rare disease database content. The Orphanet nomencla-
ture of rare diseases, whose adoption has been recom-
mended by the European Commission expert group of rare
diseases for codification of rare-disease (RD) patients in
health information systems (recommendation on ways to
improve codification for rare diseases in health informa-
tion systems: http://ec.europa.eu/health/rare diseases/docs/
recommendation coding cegrd en.pdf), is being annotated
with HPO terms in order to allow for deep phenotyping of
RD in health records and registries.
The description of phenotypic variation has become
a central topic for translational research and genomic
medicine (4–7), and ‘computable’ descriptions of human
disease using HPO phenotypic profiles (also known as ‘an-
notations’) have become a key element in a number of al-
gorithms being used to support genomic discovery and di-
agnostics. Here, we describe the latest improvements to the
tools and resources being developed by the HPO Consor-
tium and the Monarch Initiative, and provide an overview
of external tools and databases that are using the HPO for
translational research and diagnostic decision support.
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HPO: NEW TERMS, ANNOTATIONS AND ONTOLOGY
INTEGRATION
The HPO is organized as independent subontologies that
cover different categories. The largest category is Pheno-
typic abnormality. TheMode of inheritance subontology al-
lows disease models to be defined according to Mendelian
or non-Mendelian inheritancemodes. TheMortality/Aging
subontology similarly allows the age of death typically as-
sociated with a disease or observed in a specific individual
to be annotated. Finally, the clinical modifier subontology
is designed to provide terms to characterize and specify the
phenotypic abnormalities defined in the Phenotypic abnor-
mality subontology, with respect to severity, laterality, age
of onset, and other aspects.
Ontology
The HPO has grown substantially since the first Nucleic
Acids Research database article in 2014 (Version: 30 July
2013) (8) to the September 2016 release (Version: 3 Septem-
ber 2016). There are 1725 additional terms (10 088 in 30
July 2013 versus 11 813 in 3 September 2016, see Figure
1) and 2269 additional subclass relationships (13 326 ver-
sus 15 595). We obsoleted 82 HPO classes (44 versus 126).
We have added 2024 textual definitions (6603 versus 8627)
and 8063 synonyms (6265 versus 14 328). Logical defini-
tions were constructed for an additional 1126 HPO classes,
bringing the total number to 5717. These definitions refer
to ontologies for biochemistry, gene function, anatomy, and
others, and allow cross-species mapping by means of auto-
mated semantic reasoning. There are now 123 724 annota-
tions of HPO terms to rare diseases and 132 620 to common
diseases.
Annotations
The main domain application of the HPO has, to date, been
on rare disorders, and we have in the past provided a large
corpus of disease-HPO annotation profiles using OMIM,
Orphanet and DECIPHER for disease entities (8). With re-
cent advances in personalized medicine, it is becoming in-
creasingly important to provide a computational founda-
tion for phenotype-driven analysis of genomes and other
translational research in other fields of medicine. Conse-
quently, we have extended our work to common human dis-
ease phenotypes by means of a text-mining approach (9)
toward analyzing the 2014 PubMed corpus, which allowed
us to infer 132 620 HPO annotations for 3145 common
diseases (10). These annotations were validated against a
manually curated subset of disorders and experimental re-
sults showed an overall precision of 67%. We showed sta-
tistically significant phenotypic overlap between common
diseases that share one or more associated genetic variants
(‘Genome-wide association study [GWAS] hit’), as well as
phenotypic overlaps between rare and common disease that
are linked to the same genes (10). The HPO has also been
adopted by several resources for genotype-phenotype data
in the field of complex disease and genome-wide associa-
tion study (GWAS) analysis, including GWAS Central (11)
andGWASdb (12), and is likely to be adopted for phenome-
wide association studieswith electronic health records in the
future (13).
Precision annotation of deep phenotyping data
The performance of computational search algorithms
within and across species can improve if a comprehensive
list of phenotypic features is recorded. It is helpful if the per-
son annotating thinks of the set of annotations as a query
against all known phenotype profiles. Therefore, the set of
phenotypes chosen for the annotation must be as specific as
Figure 1. Distribution of HPO class additions per general category of phenotypic abnormalities. The figure shows the number of terms added per category
since the previous Nucleic Acids Research database article in 2014 (8).
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possible, and represent the most salient and important ob-
servable phenotypes. TheMonarch Initiative has developed
an annotation sufficiency meter that assesses the breadth
and depth of the phenotype annotation profile using a five-
star rating system for a given patient in the context of all cu-
rated human andmodel organismphenotypes, with the goal
of helping the annotator to generate an annotation profile
specific enough to exclude similar diseases and to identify
model organisms with similar phenotypes that may have
mutations in relevant genes or pathways (14). TheMonarch
annotation sufficiency meter is displayed within PhenoTips
(15) and PhenomeCentral (16).
Integration
The scope and specificity of phenotypes useful for diagno-
sis and clinical decisions support differ considerably from
phenotypes useful for medical billing and quality-of-care
assessment. What sets HPO apart from other ontologies
is that it is purpose built for the diagnosis and care use
case and that it is designed to facilitate cross-species com-
parisons so that non-human data can be brought to bear
as well. Moreover, to accomplish this task the HPO must
also have extremely broad coverage of concepts. In an eval-
uation of HPO content versus the numerous vocabular-
ies integrated within the Unified Medical Language Sys-
tem (UMLS), Winnenburg and Bodenreider showed that
the coverage of HPO phenotype concepts in the UMLS is
54% and only 30% in SNOMED CT (17). The UMLS is a
terminology integration system developed by the U.S. Na-
tional Library of Medicine that integrates many standard
biomedical terminologies (18). In order to improve the cov-
erage of phenotype data, the UMLS has now integrated the
entire HPO starting with the 2015AB release. This enables
an easy process to map HPO-encoded data to standard
health-care terminologies such as SNOMEDCT (19). HPO
has contributed to the establishment of the International
Consortium of Human Phenotype Terminologies (ICHPT;
http://www.ichpt.org) to provide the community with stan-
dards that achieve interoperability among databases incor-
porating human phenotypic features. The outcome is a set
of over 2300 terms which should be incorporated in any
terminology and which is fully cross-referenced with HPO
terms. These terms are not arranged in a hierarchy and so
can be mapped to or incorporated into any ontology.
The HPO project data are available at http://www.
human-phenotype-ontology.org. Requests for new terms
or other amendments can be made using the GitHub
issues tracker https://github.com/obophenotype/human-
phenotype-ontology/issues. Further information on HPO-
related publications and general announcements can
be found on the HPO website at http://www.human-
phenotype-ontology.org and on the HPO twitter feed
@hp ontology.
CLINICAL UTILITY
Although exome sequencing and other forms of genomic di-
agnostics have greatly accelerated the pace of discovery of
novel disease-associated genes and have begun to be imple-
mented in diagnostic settings inmedical genetics, the overall
diagnostic yield can still be low. It has been estimated that
the genetic cause of only about half of the currently named
∼7000 rare diseases has been identified (20,21); in order to
confidently assert that pathogenic variants in a given gene
are associated with a given Mendelian disease, the commu-
nity norm is to require the identification of at least two un-
related cases. TheHPO team therefore continues to collabo-
rate with clinical groups to refine and extend current terms
and annotations to support efforts to match patient phe-
notype and genotype data. Table 1 provides an overview of
public-facing clinical databases that use HPO to annotate
patient data.
The HPO has been extensively applied to the phenotypic
characterization of bone dysplasias (rare genetic bone dis-
orders). The BoneDysplasia Ontology (BDO) (22) is an on-
tological representation of the International Skeletal Dys-
plasia Society’s Nosology of Genetic Skeletal Disorders, the
de facto standard classification for human bone dysplasias.
The BDOusesHPO terms for the phenotypic description of
each disorder. Using the BDO and HPO, decision support
methods were developed to predict the correct bone dyspla-
sia diagnosis from a set of HPO terms, and their methods
outperformed many clinicians (23).
DECIPHER (https://decipher.sanger.ac.uk) was estab-
lished in 2004 as a web-based system for interpretation and
sharing of genomic variants and their associated pheno-
types. DECIPHER now supports sequence variation and
copy number variation in the nuclear and mitochondrial
genomes. DECIPHER was an early adopter of HPO and is
the platform through which data from the Deciphering De-
velopmental Disorders study (DDD study) is shared (24).
At the outset of the project, the DDD study (www.ddduk.
org) funded a week-long workshop to improve the HPO on-
tology by reducing redundancy of terms and improving cov-
erage in the rare disease space. DECIPHER currently has
21,689 open-access patient records annotated with 60,521
HPO-encoded phenotype observations.
PhenoTips (15) is an open-source clinical phenotype and
genotype data collection tool. It provides simple user inter-
faces to select and explore HPO annotations and suggest
diagnoses from OMIM. Records within PhenoTips can be
de-identified and pushed to PhenomeCentral (16) to partici-
pate in phenotypic and genotypic matching with other cases
in PhenomeCentral and in connected databases through
the Matchmaker Exchange. PhenomeCentral makes use of
HPO terms to measure semantic similarity between patient
phenotypes and prioritize exome data using the Exomiser.
At the time of this writing, PhenomeCentral contains 2640
matchable cases, of which 2059 have at least one HPO term,
172 are from the NIH UDP and 28 from the NIH UDN.
Patient Archive (PA) (2) is a clinical-grade phenotype-
oriented platform for managing patient data; PA combines
the richness of the HPOwith highly intuitive user interfaces
to aid the discovery and decision-making process in the con-
text of clinical genomics. PA enables clinicians to use free
text clinical notes as the starting point for structured HPO-
centric patient phenotyping to support clinical diagnostics
and care. To this end, an instance has been installed in the
Western Australian Department of Health for clinical ge-
netic use, both within and outside of, the Undiagnosed Dis-
eases Program (UDP)––Western Australia; a clinical public
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Table 1. A selection of public-facing clinical databases using HPO to annotate patient data for disease-gene discovery projects
Name URL Ref
PhenomeCentral phenomecentral.org (16)
DDD (Deciphering Developmental Disorders) www.ddduk.org (61,62)
DECIPHER (DatabasE of genomiC varIation and Phenotype in
Humans using Ensembl Resources)
decipher.sanger.ac.uk (63)
ECARUCA (European Cytogeneticists Association Register of
Unbalanced Chromosome Aberrations)
http://umcecaruca01.extern.umcn.nl:
8080/ecaruca/ecaruca.jsp
(64)
The 100 000 Genomes Project https://www.genomicsengland.co.uk/ (65)
Geno2MP (Exome sequencing data linked to phenotypic
information from a wide variety of Mendelian gene discovery
projects)
http://geno2mp.gs.washington.edu (21)
NIH UDP (Undiagnosed Diseases Program) available via phenomecentral.org (66)
NIH UDN (Undiagnosed Diseases Network) available via phenomecentral.org (16)
HDG (Human Disease Gene Website series) www.humandiseasegenes.com
Phenopolis (An open platform for harmonization and analysis of
sequencing and phenotype data)
https://phenopolis.github.io
GenomeConnect (Patient portal developed by ClinGen (67) www.genomeconnect.org (68)
FORGE Canada & Care4Rare Consortium available via phenomecentral.org (69)
RD-Connect platform.rd-connect.eu (28)
Genesis thegenesisprojectfoundation.org
health service. It has also been nominated as the platform
of choice for the UDP Australia which participates in the
Undiagnosed Diseases Network International (25). Relat-
edly, and building on the principles of founding work (26),
the integration of automated annotation of HPO terms to
3D facial images as part of a suite of approaches in the clin-
ical workflow continues to be developed through the Rare
and Undiagnosed Diseases Diagnostic Service at Genetic
Services of Western Australia (27).
Phenopolis is an interactive platform built on genomic
and phenotypic data from over 4000 patients. With the help
of phenotype quantification using HPO, Phenopolis is able
to prioritize causative genes using prior knowledge from
OMIM, Pubmed publications and existing tools such as Ex-
omiser. Additionally, it helps novel gene discovery by look-
ing for potential gene-HPO relationships among the pa-
tients without using any prior knowledge. This unbiased
approach may provide valuable information for hospitals
and researchers to optimize their resources on diagnosis and
functional studies for the relevant genetic diseases.
Numerous rare-disease research consortia are usingHPO
for patient annotation and analysis. In order to review and
expand the HPO to better represent specific disease areas,
the HPO consortium has conducted workshops with con-
sortia including the European FP7 projects RD-Connect
(28), EURenOmics and NeurOmics. Using advanced omics
technologies, NeurOmics, an EU-funded translational re-
search project, aims to characterize the causes, pathome-
chanisms and clinical features across ten major neurode-
generative and neuromuscular disease groups affecting the
brain and spinal cord, peripheral nerves and muscle. EU-
RenOmics is using high-throughput technologies to charac-
terize new genes causing or predisposing to kidney diseases,
concentrating on five groups of renal disease.
RD-Connect is an integrated platform connecting
databases, registries, biobanks and clinical bioinformatics
for rare disease research that brings together multiple
datasets on patients with rare diseases at a per-patient level.
Deep phenotyping of affected individuals is an essential
component of these projects, and is being addressed by
using the HPO as a mechanism for linking a computation-
ally accessible phenotypic record with a genomic dataset.
The projects performed a review of available ontologies at
an early stage and concluded that the HPO was the most
appropriate ontology for their gene discovery focus (28).
Both NeurOmics and EURenOmics performed mapping
exercises in order to transform data items suggested by clin-
icians as essential items to record for each patient present-
ing with a particular clinical profile into HPO terms, and in
most cases this mapping was able to produce exact matches
to an already existing HPO term. Missing areas were then
addressed in the expert workshops described above. Several
of these projects make use of PhenoTips (15) in order to
capture clinical data to a highly granular level through an
interface that is user-friendly for clinicians. Independently
of the data entry mechanism, the use of the HPO means
that the data generated by these consortia is fully inter-
operable with other datasets internationally. Currently, the
RD-Connect platform contains∼2000 exome, genome and
panel sequencing datasets linked with HPO-coded pheno-
typic profiles from a range of rare diseases.
The HPO was used within the EuroEPINOMICS-Rare
Epilepsy Syndrome (RES) project to systematically as-
sess phenotypes in patients with epileptic encephalopathies
(29,30). A first analysis of clustering of epilepsy phenotypes
was presented as a poster at the 2012 European Congress
of Epileptology (31), while a more comprehensive analy-
sis of the obtained HPO terms including exome sequenc-
ing data is currently underway. Clustering of patient pheno-
types in 171 patients with epileptic encephalopathies iden-
tified a subgroup of eight patients with closely related phe-
notypes. A review of manually curated phenotype data sug-
gested these patients had a subset of Infantile Spasms with
a good outcome. This preliminary analysis suggested that
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the use of HPO terms in patients with epilepsy is worth-
while, given that the identified epilepsy phenotype was both
homogeneous and clinically meaningful.
The use of HPO terms for patients with epilepsy is chal-
lenging. In contrast to many other genetic disorders, the
phenotypic features in epilepsy patients are dynamic and
specific features such as a complex seizure semiology are of-
ten difficult to fully include in systematic phenotype ontolo-
gies. For example, a patient with simple febrile seizures may
have self-limiting febrile seizures (FS), may have recurrent
febrile seizures past the age of six years (FS+), or may de-
velop the intractable, fever-related epilepsy of Dravet Syn-
drome over time. All three entities are distinct, but depend-
ing on the age of the patients,may be coded identically in the
HPO if modifiers coding the patient’s age are not used. The
dilemma of fully representing dynamic neurological pheno-
types emphasizes the need for the ongoing use ofHPOmod-
ifiers to achieve dimensionality in phenotype data.
The HPO has been used to incorporate clinical data
into the analysis of a diagnostic next-generation sequencing
panel with nearly all known Mendelian disease-associated
genes; the algorithm, Phenotypic Interpretation of Exomes
(PhenIX) contributed to a diagnostic rate of 28% in chil-
dren in whom previous extensive workups had failed to re-
veal a diagnosis (32). Using HPO to generate individualized
phenotype-driven gene panels for diagnostics led to an in-
crease in the diagnostic yield (33).The ThromboGenomics
Consortium reported that computational prioritization of
candidate rare variants identified in patients with bleeding,
thrombotic or platelet disorders using HPO-coded pheno-
types assigned the highest scores to pathogenic or likely
pathogenic variants in 85% of cases, demonstrating that
HPO-based algorithms can make multidisciplinary diag-
nostic meetings more efficient (34).
Once such a causative link between rare pathogenic vari-
ants in a given gene has been established, it is essential to as-
sess the clinical variability attributed to other mutations in
that gene. For this, several novel approaches have currently
been developed, such as the Human Disease Gene Web-
site series (HDG). HDG is an international library of web-
sites (www.humandiseasegenes.com) for professional infor-
mation about genes and copy number variants and their
clinical consequences using HPO to annotate the pheno-
type. Here, professionals will find relevant information that
helps with interpretation of variants and counseling of their
patient/families with such a rare genetic disorder and also
have the opportunity to share clinical data. Moreover, pa-
tients, parents, and caregivers will find useful information
on the rare genetic disease in their family.
Sanford Health, one of the largest non-profit rural health
care systems in the United States, has embarked on clinical
genotyping of a substantial portion of its patient popula-
tion to provide precision prevention and pharmacogenet-
ics. As part of this process, it has incorporated tools within
the patient portal of the electronic medical record (EMR)
to enable patients to characterize themselves in HPO. Simi-
larly, it has incorporated Phenotips within the EMR to en-
able clinical staff to characterize in HPO all patients pre-
scribed diagnostic molecular testing. For both the patient
self-characterization and the clinician characterization, the
Monarch Initiative sufficiency score is used to guide depth
of characterization. The HPO terms, data within the EMR
andmolecular test results are integrated to define diagnoses
and best practice guidelines entered into the EMR.
The 100 000 Genomes Project (www.genomicsengland.
co.uk) is sequencing 100 000 whole genomes fromNHS pa-
tients in England with rare diseases or cancer. Recruitment
to the Rare Disease Programme currently occurs across ap-
proximately 200 diseases. A vital aspect of the project is
to link rare disease participants’ genomes with their phe-
notype profile to enable genome diagnostics and in-depth
genotype-phenotype analyses. The phenotype profiles need
to be detailed, specific, consistently applied, computation-
ally accessible and concordant with existing standards. The
project has developed HPO-based models for each rare dis-
ease. These comprise, typically, 20–40 HPO terms that de-
scribe the key features of the disease. These are presented
to recruiting clinicians as a questionnaire––additional HPO
terms can also be entered. This approach requires less prior
knowledge of HPO to achieve in-depth phenotyping than
simple ‘free entry’, and encourages recording of the ab-
sence of phenotypes as well as their presence. The models
are typically developed by mapping HPO terms to an exist-
ing case report form, published review, registry schema or
through interaction with clinical experts. Models are anal-
ysed to ensure practicality, consistency and specificity using
the Monarch annotation sufficiency score described above.
Where clinical terms that are not contained in HPO are
identified during model development they are submitted for
inclusion. The collected phenotypes for each program par-
ticipant are used extensively in analysis pipelines, and for
manual clinical interpretation and automated prioritization
using algorithms such as Exomiser (35) and Phevor (36).
USE OF HPO IN GENE IDENTIFICATION RESEARCH
TheHPOhas been used inmanyways in research on disease
pathophysiology, diagnostics and gene-discovery projects.
It has been used to provide lists of genes associated with
one or more HPO terms in order to filter lists of candi-
date genes (37–39), to prioritize candidate genes in Exome-
sequencing studies via PhenIX, Phevor or Exomiser (40–
43), and to identify known or novel disease genes or to
analyze structural variation in large cohorts (44–46). The
Deciphering Developmental Disorders (DDD) study ana-
lyzed 4125 families with diverse developmental disorders
and identified four novel disease-gene associations by com-
bined analysis of the genotypes and the phenotypic simi-
larity of patients with recessive variants in the same candi-
date gene (47). The BRIDGE-BPD Consortium (48) used
genome sequencing combined with HPO coding to iden-
tify a gain-of-function variant inDIAPH1 in two unrelated
pedigrees with deafness and macrothrombocytopenia (49).
This finding was supported by Phenotype Similarity Re-
gression (SimReg), an algorithm for identifying composite
phenotypes associated with rare variation in specific genes
(50). HPO-based phenotype analysis also allowed match-
ing of human phenotypes to mouse phenotypes by cross-
species analysis and thereby aided the discovery of a domi-
nant gain-of-function mutation in SRC that causes throm-
bocytopenia, myelofibrosis, bleeding and bone abnormali-
ties (51).
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Table 2. Tools and applications using HPO
Tool Reference
Phenotype-driven differential diagnosis
Phenomizer (70)
BOQA (71)
FACE2GENE (72)
Phenolyzer (73)
Phenotype-driven exome/genome analysis
Exomiser (35,74)
PhenIX (32)
Phevor (36)
PhenoVar (75)
eXtasy (76)
OMIMExplorer (77)
Phen-Gen (78)
Geno2MP (21)
Genomiser (79)
SimReg (50)
ontologySimilarity *
Functional and network analysis
TopGene/ToppFunn (80)
WebGestalt (81)
SUPERFAMILY (82)
GREAT (83)
Random walk on heterogeneous network (84)
PANDA (85)
PREDICT (86)
Clinical data management and analysis
Phenotips (15)
Patient Archive (2)
GENESIS (GEM.app) (87)
Cross-species phenotype analysis
PhenoDigm (88)
MouseFinder (89)
Monarch (2,53)
PhenomeNet (90)
UberPheno (56)
MORPHIN (91)
PhenogramViz (92)
Phenotype knowledge resources and databases
Orphanet (3)
MalaCards (93)
NIH genetic testing registry (94)
OMIM (95)
dcGO (96)
ClinVar (97)
GeneSetDB (98)
MSeqDR (99)
DIDA (digenic diseases database) (100)
Genetic and Rare Diseases (GARD) Information Center (101)
Visualization
PhenoStacks (102)
PhenoBlocks (103)
DECIPHER (phenogram) (63)
phenogrid (2)
ontologyPlot *
*Greene, D., Richardson, S. and Turro, E. OntologyX: a suite of R packages for working with ontological data, under review.
The Matchmaker exchange (MME) platform provides a
systematic approach to rare disease-gene discovery with a
federated network of phenotype-genotype databases that
enable data sharing and discovery of relevant data (52,53)
over a secure API (54). TheHPO is the standard vocabulary
for communicating phenotype data. The MME currently
connects over 30 000 rare disease cases across six different
patient databases.
TRANSLATIONAL RESEARCH AND DIAGNOSTICS
WITH HPO: ALGORITHMS AND TOOLS
The HPO is a computational resource that allows algo-
rithms to ‘compute over’ clinical phenotype data in an in-
creasing number of contexts through a growing number of
tools from theHPOConsortiumand other groups (Table 2).
The tools use the ontological structure of the HPO that al-
lows individual terms to be associated with an information
content, ameasure of specificity (55), or with the underlying
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Table 3. NIHR-RD-TRC assessment scale
Stage Description Example
Foundation The basis of characterizing the disease in HPO needs to
be developed
HPO is good for describing dysmorphologies especially
across species: how do you model and use dyslexia?
Formulation The theory is defined but key details need to be defined
and handled in the ontology computations
HPO models biology, where diseases are caused by
environmental factors, e.g. cancers –– how can an
environment ontology be included?
Refinement The key data sets and definitions for the disease are
identified and available but require ‘translation’
Theme based registry systems hold collections of data in
other coding systems (registry-specific or ICD) –– how
can these be mapped onto HPO?
Maturity The HPO framework is in place and productive results
are being obtained, the HPO term set continues to evolve
The HPO basics are in place and a set of Phenotypes in
place –– do we need more terms or do existing terms need
modification?
Table 4. NIHR-RD-TRC assessment of HPO maturity
Theme Foundation Formulation Refinement Maturity
Cancer  
Cardiovascular   
Central Nervous System 
Eye Diseases    
Gastrointestinal  
Immunological Disorders   
Paediatric (cross-cutting)    
Metabolic & Endocrine Diseases  
Musculoskeletal Disorders   
Muscle & Nerve Diseases   
Non-malignant Haematology    
Renal    
Respiratory Diseases  
Skin Diseases   
logical definitions of the terms, such that HPO terms can be
linked to other resources such as model organisms (56,57).
PUBLISHING PROCESSES AND DATA EXCHANGE
It is non-trivial to collect patient phenotypes reliably,
whether retrospectively from existing medical data or
prospectively. The overwhelming majority of clinical de-
scriptions in the medical literature are available only as nat-
ural language text, meaning that searching, analysis and
integration of medically relevant information is challeng-
ing. An important step to increase the amount and qual-
ity of phenotype data in databases is to obtain the rele-
vant information from authors upon submission of articles.
The journal Cold Spring Harbor Molecular Case Studies
requires authors to select HPO terms for research papers
that are displayed alongside the manuscript and that can be
used to search journal content for other cases with overlap-
ping HPO terms (58). Short Reports inClinical Genetics re-
quire authors to submitHPO-coded phenotype data to Phe-
nomeCentral (16). An important goal of the HPO and the
Monarch Initiative is to provide computational standards
that will allow for exchange of detailed genotype and phe-
notype data by means of the emerging PhenoPackets stan-
dard (http://phenopackets.org).
PATIENT PHENOTYPING
Patient-reported phenotype data in patient registries such
as J-RARE for rare diseases has been increasingly exploited
in scientific research; for instance, indicating symptoms still
unknown to physicians. A barrier to the use of patient-
reported data for understanding the natural history and
phenotypic spectrum of diseases lies in the fact that clini-
cal terminology is often unfamiliar to patients. The HPO
consortium has therefore increased the usability of theHPO
by patients, as well as scientists and clinicians, by systemati-
cally adding new, ‘plain language’ terms, either as synonyms
to existing classes or by tagging existing HPO class labels as
”layperson”. These layperson terms provide increased ac-
cess to the HPO––for example, a patient may know they are
‘color-blind’, but may not be familiar with the clinical term
‘Dyschromatopsia’. As a result of this effort, the HPO now
contains over 6000 layperson terms that can be integrated
into patient registries, making the terminology useful for
data interoperability across clinicians and patients. Future
work will include validation studies using data from patient
registries to demonstrate the utility of the HPO layperson
synonyms in informing rare disease diagnosis (59).
HPO: AN ASSESSMENT BY THE NIHR RARE DIS-
EASE INITIATIVES
HPO is used as the system to capture of phenotypic infor-
mation for the UK’s National Institute for Health Research
(NIHR) Rare Disease initiatives on projects such as NIHR
RD-TRC (Rare Disease––Translational Research Collabo-
ration, http://rd.trc.nihr.ac.uk) and the NIHR BioResource
Rare Disease NIHR BR-RD. HPO is employed in all of
these broad wide-ranging studies and includes data inte-
gration from a variety of sources such as multiple EHR
systems, in a variety of locations and specialities. In some
disease areas, for example, bleeding and platelet disorders,
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HPO has been the platform for new gene discovery and in-
novative research findings (44); the advantage of HPO its
support for statistical power associations across phenotypes
across different diseases and in different branches of the
HPO ontology.
The NIHRRare Disease initiatives use a common infras-
tructure and clinical coding for the RD-TRC (56 studies),
BR-RD (14 studies) and also in our contribution to the 100
000 Genome project (160+ targeted diseases, as mentioned
above). This produces a large and diverse dataset with a
growing ‘data dictionary’ containing terms mapped across
different systems and coding schemes and includes clinically
relevant signs outside of HPO––for example, lab test results
or exercise questionnaires.
In a short update, it is difficult to present the breadth of
the contribution HPOmakes to NIHR-RD research, which
indeed is growing as more diseases are characterized and
encoded using HPO. The HPO is now being employed in
numerous NIHR-RD studies and it is anticipated that its
use will be extended into all studies in which phenotype data
are captured.
The NIHR-RD-TRC has developed a qualitative scale
for thematurity ofHPO across different disease areas which
adopts a four stage assessment (Table 3). The current, sub-
jective, assessment of HPO maturity by the NIHR RD-
TCR is shown in Table 4. The assessment will be used to
prioritize areas requiringmost attention in our future work.
FUTURE DEVELOPMENTS AND OUTLOOK
Development of the HPO has continued steadily since its
initial publication in 2008 (1), and has focused on providing
a well defined, comprehensive, and interoperable resource
for computational analysis of human disease phenotypes,
and has been used as a basis for a wide panoply of tools
to perform analysis in clinical and in research settings. The
HPO has been adopted by a growing number of groups in-
ternationally, and efforts are underway to translate theHPO
into six languages, as we will report on in the future.
Orphanet serves as a reference portal for rare diseases
populated by literature curation and validated by interna-
tional experts (3). TheHPOproject andOrphanet are work-
ing on the creation of an integrated RD-specific informatics
ecosystem that will build on the HPO as well as the Or-
phanet Rare Disease Ontology (ORDO), an open-access
ontology developed from the Orphanet information system
(60).
While the initial focus of the HPO was placed on rare,
mainly Mendelian diseases, HPO annotations are now
available also for 3145 common diseases (10). Current work
will involve the extension of HPO resources for precision
medicine, cancer, and disorders such as congenital heart
malformations that are characterized by non-Mendelian in-
heritance.
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